Aclid
United StatesFounded 2021Industry
Aclid provides software that automates DNA synthesis screening and biosecurity compliance. CBRNE-relevant work is a primary business line according to its website.
What it does
Profile
Aclid is a biosecurity and compliance automation platform for DNA and RNA synthesis providers. It screens synthesis orders for pathogenic or toxic sequences and automates related compliance checks.
More profile
The company was founded in 2021 by an entrepreneur and a Columbia University professor. In October 2023 it announced an oversubscribed seed round of 3.3 million dollars led by 2048 Ventures and IA Ventures.
It also appears in the US Small Business Innovation Research portfolio, which indicates federal small-business research funding, though the award details were not read. The company's headquarters city is not confirmed in the sources read.
Ownership
Privately held; venture-backed (seed round led by 2048 Ventures and IA Ventures, October 2023)
Parent: none identified
Sources (4)
Not verified or not found
- Headquarters city: not confirmed.
- SBIR award agency, amount and date: not read.
- Customers and any development in the last 24 months: not read.
Questions
What does Aclid do?
Aclid provides software that automates DNA synthesis screening and biosecurity compliance. CBRNE-relevant work is a primary business line according to its website.
Where is Aclid based?
HQ country: US.
Who owns Aclid?
Privately held; venture-backed (seed round led by 2048 Ventures and IA Ventures, October 2023). Parent: none identified
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction